BRAF and melanoma: Current guidelines advocate for the utilization of PD-1 blockade (nivolumab, pembrolizumab), PD-1 blockade in combination with CTLA-4 blockade (nivolumab–ipilimumab), PD-1 blockade in combination with LAG-3 blockade (nivolumab–relatlimab), and, for BRAF-mutated melanoma, BRAFi (vemurafenib, dabrafenib, encorafenib) combined with MEKi (cobimetinib, trametinib, binimetinib) in the first or second line treatment [4,5].